Company intelligence / Profile preview
Neurentis
London, England, UKneurentis.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Neurentis is developing a late-stage transdermal patch for treatment-resistant depression and leveraging AI to discover new antidepressants. They also have a program targeting oxytocin receptors with potential applications across multiple neuropsychiatric and behavioral indications. The company focuses on innovative approaches to address unmet needs in mental health, particularly where current treatments are insufficient.
- Therapeutic areas
- PsychiatryRare Diseases
- Modalities
- Small moleculesTransdermal patchAI-driven drug discovery
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Neurentis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurentis.